Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

Compugen Ltd. announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody. Japanese patent No. JP7348072B2, titled "Triple Combination Antibodies Therapies" augments previously issued patent in Japan by expanding and protecting Compugen's differentiated and leading triple blockade of the DNAM-1 axis with any anti-PVRIG in combination with any anti-TIGIT and anti-PD-1 antibody.

Japanese patent No. JP7348072B2 is expected to expire no earlier than June 2038.